KESTRA MEDICAL TECHNOLOGIES LTD (KMTS)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for KMTS
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| KMTS | Director | 67 | [] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
Biography sourced from the proxy statement filing.
ee and the chair of our compensation committee. Additionally, Mr. Cohen was a member of the board of directors of our subsidiary, Kestra Medical Technologies, Inc., from 2024 to 2025. Mr. Cohen is an accredited public company director and currently serves on the board, including the audit and compensation committees, of RxSight (Nasdaq: RXST), a medical technology company that makes and markets adjustable intraocular lens to customize vision after cataract surgery. He is the chairman of the board of directors of a number of privately held companies, including Biobeat Technologies, Spiro Medical, Archimedes Vascular, Resonant Link Medical and ExNuero. In addition, Mr. Cohen is also an Operating Partner of the venture fund Star51 Capital as well as a Venture Partner with Andera Partners (Paris) and Sherpa Capital Partners (Beijing). From 2013 to late 2024, Mr. Cohen was the Chief Executive Officer and a member of the board of directors of Axonics, Inc. (Nasdaq: AXNX), a medical device company employing implantable neurostimulation to treat bladder and bowel disorders, during which time he oversaw the company s initial public offering in 2018 and led the company s sale to Boston Scientific Corporation (NYSE: BSX) ("Boston Scientific") in late 2024. Mr. Cohen also served as chairman of the board of SoniVie, Ltd., an Israeli medical device company sold to Boston Scientific in May 2025 and Nalu Medical sold to Boston Scientific in October 2025. Earlier in his career, Mr. Cohen served almost a decade as the CEO and Chairman of Cardiac Science, Inc. (formerly NASDAQ: DFIB), a manufacturer of automated external defibrillators, now owned by Zoll Medical. He was also previously the chairman of BioLife Solutions, Inc. (Nasdaq: BLFS) and held board positions at Spectrum Pharmaceuticals (Nasdaq: SPPI) and LifeWatch (LIFE.SW), as well as private companies including Syncroness, Inc. Mr. Cohen received his B.S. in Business Management from Binghamton University. We believe Mr. Cohen is qualified to serve on our Board based on his decades of experience as a medical technology executive and as a board member of medical technology companies.